The company will now focus on specialty products in Japan; it is open to inorganic opportunities, especially in India. Pharma major Lupin has divested its entire stake in its Japanese subsidiary,......
This acquisition marks Lupin's foray into the Japanese branded market in-line with aspirations to build business globally. Kyowa Pharmaceutical Industry, drug major Lupin's Japanese subsidiary, has......
Japan, the world's third largest and one of the most regulated pharmaceutical markets globally, is emerging as the new attractive destination for Indian drug majors. The $60 billion Japanese pharma......